Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, three patients with extensive alopecia areata showed varying degrees of hair regrowth after 20 weeks of treatment with ustekinumab, a cytokine-targeting therapy.

This study in Mexican patients with alopecia areata found that body hair involvement was linked to disease progression, while treatment adherence was associated with both remission and progression.

This study found that patients with alopecia areata who have low vitamin D levels and high CRP levels are more likely to develop the universalis form of the condition, indicating a need for more aggressive treatment in these cases.

This study reports that yellow dots in a higher number per field of vision were the most consistent dermoscopic finding in severe cases of alopecia areata.

This study surveyed German dermatologists about treating children and adolescents with alopecia areata, revealing significant emotional challenges like bullying and low self-esteem, dissatisfaction with available treatments, and a need for both psychological support and new therapeutic guidelines.

In this study, tofacitinib was reported to improve scalp hair regrowth in patients with severe alopecia areata, alopecia totalis, and alopecia universalis, showing a higher response in alopecia areata.

This article reviews current and emerging treatments for alopecia areata, including Janus kinase inhibitors, highlighting variability in clinical outcomes and the lack of sustained remission.

This study analyzed survey responses from 800 alopecia areata patients and found a possible genetic association with increased insulin-dependent diabetes mellitus in relatives but not in the patients themselves.

This study found that monthly oral prednisolone pulses of 300 mg were effective and safe for treating widespread alopecia areata, with 58.3% of patients achieving cosmetically acceptable hair growth.

This consensus statement outlines a treatment algorithm for alopecia areata, discussing when to consider systemic treatment and how to assess outcomes, without providing new clinical results.

This review discusses the psychological impact of alopecia on women and reports no new clinical findings, highlighting the effect on self-esteem and quality of life.

This article reviews the diagnosis and management of alopecia areata but reports no new research findings.

This study found that diphenylcyclopropenone therapy resulted in over 50% hair regrowth in 71% of alopecia totalis patients, with a significant relapse association with thyroid disease, suggesting treatment could be viable but should continue for at least two years.

This review explores the efficacy and outcomes of using JAK inhibitors for treating alopecia areata, noting advancements in understanding the disease's pathomechanisms and suggesting that JAK inhibitors may offer targeted therapeutic benefits by blocking specific inflammatory pathways involved in this chronic condition.

This study observed a strong negative association between the HLA-DQB1*0201 allele and the alopecia totalis/alopecia universalis phenotype in Caucasian individuals, indicating a potential protective role.

This review discusses immune pathways involved in alopecia areata and explores emerging, more targeted therapeutic strategies, noting their potential for better safety and effectiveness compared to traditional immune suppressants.

This review summarizes findings on the long-term use of tofacitinib for severe alopecia areata, reporting its potential as a promising treatment option.

This study reports two cases of hair loss outcomes in patients using dupilumab for atopic dermatitis, with one showing improvement in alopecia universalis and another experiencing worsening of alopecia totalis.

This study found that a combination therapy of oral corticosteroid and oral PUVA led to scalp hair regrowth in patients with intractable alopecia totalis and universalis within two months.

This study reviewed existing articles to assess the efficacy of topical diphenylcyclopropenone immunotherapy for alopecia areata, but it did not report new clinical results.

This study found that monthly high-dose steroid pulse therapy for approximately six months was effective and well-tolerated in Taiwanese patients with severe multifocal alopecia areata.

In this study, oral steroid pulse therapy was found to be as effective and well-tolerated as intravenous pulse therapy in treating severe alopecia areata, especially when started within one year of disease onset.

This study reports that horizontal sections of scalp biopsies improve the diagnosis of alopecia areata, especially when characteristic inflammatory infiltrates are missing.

This report describes two young women with severe psoriasis and alopecia universalis, highlighting the possible but unstudied association between alopecia areata and metabolic syndrome.

This article is a letter to the editor about high-dose pulsed corticosteroid therapy combined with methotrexate for severe childhood alopecia areata and provides no new clinical results.

This study found that topical diphenylcyclopropenone is an effective treatment for extensive alopecia areata, with significant hair regrowth reported in most patients, though effectiveness varied with disease characteristics.

This editorial proposes a new classification for alopecia areata that incorporates the SALT score and body hair involvement, aiming to improve the assessment and treatment outcomes.

This review discusses the clinical presentations of alopecia areata, introduces guidelines for treatment studies, and explores potential changes in cutaneous innervation, but reports no new clinical results.

This study found that tofacitinib effectively induced hair regrowth in 62.2% of severe alopecia areata patients in Saudi Arabia after six months, with higher baseline Severity of Alopecia Tool scores and past steroid use linked to reduced response.

This study reported that patients with alopecia areata or alopecia totalis/universalis have a slightly increased overall cancer risk compared to controls, with specific increases in thyroid, bladder, and prostate cancers depending on the alopecia type.